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Edited by Frances ShannonAbstract Plasminogen activator inhibitor (PAI)-1 promotes
development of asthma. PAI-1 mRNA and protein are markedly
induced in activated mast cells (MCs), a major eﬀector cell type
in asthma. However, regulatory mechanisms of PAI-1 transcrip-
tion in MCs are unknown. We present ﬁrst evidence that PAI-1
is transcriptionally regulated in human MCs (hMCs). In addition
to three enhancer regions, we demonstrated that the E-box at
566 bp to 561 bp is the negative regulatory element, and
the speciﬁc and constitutive binding of the upstream stimulating
factor-1-to this E-box is the key mechanism of the negative reg-
ulation of PAI-1 expression in hMCs.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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The pathogenesis of asthma involves airway inﬂammation
and tissue remodeling [1]. Recent evidence indicates that the
plasminogen activator (PA) system is involved in inﬂammation
and tissue remodeling [2]. Plasminogen activator inhibitor-1
(PAI-1) is a major inhibitor of the PA system. We previously
demonstrated that the PAI-1 levels are markedly elevated in
the airways of human and murine asthma [3,4]. Others also
demonstrated that PAI-1 expression is increased in allergic
rhinitis [5,6]. Depletion of PAI-1 reduces the inﬁltration of
inﬂammatory cells and collagen deposition in these mice, indi-
cating that PAI-1 promotes airway inﬂammation and tissue
remodeling.
MCs are major eﬀector cells in asthma and other allergic dis-
eases. We and others discovered that the PAI-1 gene is induced
at the highest level among the inducible hMC genes [3,7]. We
showed that MCs secrete abundant amounts of PAI-1 in theAbbreviations: EMSA, electrophoretic mobility shift assay; hMCs,
human mast cells; NRE, negative regulatory element; PA, plasminogen
activator; PAI-1, plasminogen activator inhibitor-1; TFE3, transcrip-
tion factor E3; USF, upstream stimulating factor; WT, wild-type
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doi:10.1016/j.febslet.2007.08.034airways of murine model of asthma. PAI-1 production is two-
fold lower in the airways of MC-deﬁcient mice after ovalbumin
challenge compared with that in wild-type (WT) mice [4].
These ﬁndings suggest that MCs are a major source of PAI-1
in asthma. A number of cis-acting elements that positively or
negatively regulate PAI-1 transcription have been reported in
various cell types [8–16]. However, cis-acting elements respon-
sible for PAI-1 expression in MCs are unknown.
In the present study, we present ﬁrst evidence that PAI-1 is
transcriptionally regulated positively via sequences encompass-
ing 800 bp to 589 bp, 489 bp to 224 bp, and 162 bp to
41 bp and negatively via a sequence encompassing 589 bp
to 489 bp of the PAI-1 promoter in hMCs and that speciﬁc
and constitutive binding of the upstream stimulating factor-1
(USF-1) to the E-box at 566 bp to 561 bp is the key mech-
anism of the negative regulation of PAI-1 expression.2. Materials and methods
2.1. Reagents
DMRIE-C transfection reagent was from Invitrogen (Grand Island,
NY). Dual-Luciferase Assay Kit, luciferase report vectors pGL3-Basic,
pGL3-Control and pRL-CMV were from Promega (Madison, WI).
Ionomycin, phosphatase and poly (dI-dC) were from Sigma (St. Louis,
MO). Ionomycin was dissolved in ethanol at 2 mM as stock. USF-1
consensus and mutant oligonucleotides, rabbit anti-USF-1, anti-
USF-2 and anti-transcription factor E3 (TFE3) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA).
2.2. Human mast cell culture and stimulation
Human mast cell line HMC-1 cells (a kind gift from Dr. J. H. But-
terﬁeld, Mayo Clinic, Rochester, MN) were maintained as described
[3]. HMC-1 cells were stimulated with 2 lM ionomycin for 12 h or
the indicated times.
2.3. Plasmid constructions
To engineer a series of 5 0-deletion PAI-1 promoter luciferase reporter
constructs, including pGL3-Basic-589, -552, -524, -489, -224, -162, -104,
-70, and -41, PCR reaction was performed using a PAI-1 promoter
luciferase construct containing 5 0 ﬂanking800 bp to +71 bp of human
PAI-1 promoter inserted in pGL3-Basic vector (pGL3-Basic-800), a
kindly gift from Dr. A. Le (University of Southern California, Los
Angeles, CA). To generate PAI-1 promoter-luciferase reporter con-
structs containing 3.0 kb (pGL3-Basic-3.0K) and 1.3 kb (pGL3-Basic-
1.3K), we used the pGLuc3.0K which contains 3.0 kb to +71 bp of
the PAI-1 promoter (a kind gift from Dr. D. Vaughan, Vanderbilt Uni-
versity, Nashville, TN) as the PCR template. The primers used for con-
structions are summarized in Table 1. To generate pGL3-Control
PAI-1/553WT and pGL3-Control PAI-1/553EMu, double stranded
deoxyoligonucleotides for WT PAI-1 promoter fragment 553 bp toblished by Elsevier B.V. All rights reserved.
Table 1
Primers used to amplify and subclone diﬀerent regions of human
PAI-1 promoter
Region ampliﬁed Primer sequences (50–30)
41 CGCGAGCTCTGCCCACATCTGGTATAAAA
70 CGCGAGCTCGGGGCTGGAACATGAGTTCA
104 GTTGAGCTCTGTTCAGACGGACTCCCAGAG
162 CGCGAGCTCCACACACACATGCCTCAGCAA
224 CGCGAGCTCGGTTTGCTCAATTGTTCCTGAA
489 GTTGAGCTCTCCAGAGCACCGGGTGGAC
524 CGCGAGCTCCAGGAGGAGGGAGGGGCG
552 CGCGAGCTCGCATGCCCTGTGGCTGTT
589 CGCGAGCTCCTAGACAGACAAAACCTAG
800 CGCGAGCTCAAGCTTACCATGGTAACCCC
1.3 kb CGCGAGCTCGCTCCCTATGAGAATCTAATGC
3.0 kb CGCGAGCTCGAGTGCAATAGCATGATCTCGG
+71* CGCAGATCTCAGCTGCTGGAGGGGGGCGT
The asterisk indicates the common antisense primer for all constructs,
and the underlined sequences represent the restriction enzyme sites
used for subcloning (SacI and BglII).
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sticky Sac I and Bgl II sites were synthesized, annealed, and ligated
to pGL3-Control vector digested with Sac I and Bgl II. Each construct
was sequenced for veriﬁcation and orientation.
2.4. Site-directed mutagenesis
pGL3-Basic-800EMu and pGL3-Basic-589EMu were generated by
dinucleotide substitution (CACGTGﬁ CAATTG) at the E-box
(566 bp to 561 bp) of the pGL3-Basic-800 and -589, respectively,
using QuikChange Site-Directed Mutagenesis Kit (Stratagene Inc.,
San Diego, CA). Primers used for the site-directed mutagenesis were
as follows with the E-box underlined and the mutated nucleotides in
bold: sense, 5 0CCTAGACAATCAATTGGCTGGCTGCATG3 0; anti-
sense: 5 0CATGCAGCCAGCCAATTGATTGTCTAGG3 0. Mutagen-
esis was conﬁrmed by DNA sequencing.
2.5. Transient transfection of HMC-1 cells with DMRIE-C and
luciferase assay
HMC-1 cells (2 · 106 cells/well) were transfected using DMRIE-C in
the 6-well plate according to the manufacturer’s protocol (Invitrogen).
Brieﬂy, 10 ll DMRIE-C was diluted in 500 ll Opti-MEM I Reduced
Serum Medium (Invitrogen), and 4 lg of pGL3-Basic or pGL3-Con-
trol PAI-1 promoter constructs and 20 ng of Renilla luciferase reporter
vector pRL-CMV (an internal control) were diluted in another 500 ll
Opti-MEM I Reduced SerumMedium. The complexes were formed by
mixing diluted DMRIE-C and DNA gently followed by 45 min
incubation at room temperature. HMC-1 cells were washed with
serum-free growth medium without antibiotics and added to DNA–
DMRIE-C complexes. After 5 h incubation at 37 C in the CO2 incu-
bator, 2 ml culture medium containing 15% FBS was added to eachLu
-1.3 kb
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Fig. 1. Schematic diagram of 5 0-deletion PAI-1 promoter constructs and f
transfected into HMC-1 cells. Transfected cells were stimulated with 2 lM of
in Section 2. Results represented means ± S.E. of at least four independentwell. Twenty-four hours after transfection, cells were stimulated with
2 lM ionomycin or the equal volume of ethanol as control, and the
ﬁnal concentration of ethanol was 0.1% (V/V). The luciferase activities
were measured using Dual-Luciferase Reporter Assay System 12 h
after stimulation according to the manufacturer’s manual (Promega).
Final ﬁreﬂy luciferase activities were normalized to corresponding
Renilla luciferase activities, and the relative transcriptional activity of
each construct was expressed as the ratio of the normalized luciferase
activities between pGL3-Basic-3.0K to pGL3-Basic-70 and pGL3-Ba-
sic-41 (minimal PAI-1 promoter construct). To study the eﬀect of
USF-1 on PAI-1 transcription, HMC-1 cells were cotransfected with
2 lg human USF-1 expression vector pSG5-hUSF-1, the gift of Dr.
N. Chen (MD Anderson Cancer Center, Houston, TX) [17], and
pGL-3 Basic-PAI-1 promoter constructs. Experiments were performed
at least three times independently.
2.6. Nuclear protein puriﬁcation and radiolabeled probe preparation
Nuclear proteins were prepared from 2 · 107 HMC-1 cells after stim-
ulation with 2 lM ionomycin or equal volume of ethanol for 2 h using
Qproteome Nuclear Protein Kit (Qiagen, Valencia, CA). The oligonu-
cleotides representing 37 bp PAI-1 promoter fragment (589 bp to
553 bp), 5 0-CTAGACAGACAAAACCTAGACAATCACGTGG-
CTGGCT-3 0, were synthesized, annealed, and then radiolabeled with
Redivue 32P-dCTP and Rediprime II Random Prime Labelling System
(Amersham, Buckinghamshire, UK).
2.7. Electrophoretic mobility shift assays (EMSA)
Ten micrograms of nuclear proteins was incubated with 32P-labeled
37 bp dsDNA probe in 20 ll of binding buﬀer (10 mM Tris–HCl, pH
7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA) containing 1 lg poly
(dI-dC) for 20 min at room temperature and the resulting protein/
DNA complexes were then separated by electrophoresis on 6% non-
denaturing polyacrylamide gel. For competition assay, 50-fold molar
excess of unlabeled oligonucleotide was used. For supershift assays,
2 lg of USF-1, USF-2, and TFE3 antibodies were preincubated with
nuclear proteins. To study the role of phosphorylation in DNA-bind-
ing activity of USF-1, nuclear proteins were incubated with 0.2 or
0.02 U of phosphatase before adding radiolabeled probes.
2.8. Statistical analysis
Results were expressed as means ± S.E. Diﬀerences between two
groups were identiﬁed with a paired Student’s t-test. Signiﬁcance was
deﬁned as P < 0.05.3. Results
3.1. PAI-1is transcriptionally regulated in HMC-1 cells
As shown in Fig. 1, pGL3-Basic-3.0K, -1.3K, and -800
showed similarly elevated levels of PAI-1 promoter activity
in transfected HMC-1 cells. This suggests that the sequences0 5 10 15 20 25
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unctional assays. PAI-1 promoter luciferase reporter constructs were
ionomycin for 12 h. The luciferase activities were measured as described
experiments.
Fig. 2. Identiﬁcation of the E-box as the critical motif of the NRE in
HMC-1 cells. (A) HMC-1 cells were transfected with pGL3-Basic-589,
-552, -524, and -489, and then stimulated with ionomycin or vehicle for
12 h. The columns and vertical bars represent means ± S.E. of ﬁve
separate replicates. *P < 0.05 vs. pGL3-Basic-552, -524, and -489. (B)
HMC-1 cells were transfected with pGL3-Basic-41, -800, or -800 EMu.
Values were expressed as means ± S.E. of four individual experiments.
*pGL3-Basic-800 EMu showed higher promoter activity than pGL3-
Basic-800 (P < 0.05). (C) PAI-1 promoter fragment 589 bp to
553 bp with WT or mutated E-box (CACGTGﬁ CAATTG) was
inserted into the upstream of the SV40 promoter of luciferase reporter
vector pGL3-Control (PAI-1/553WT and pGL3-Control PAI-1/553
EMu, respectively). The relative luciferase activity of pGL3-Control
without ionomycin stimulation was set as 100%. Values were expressed
as means ± S.E. of four individual experiments. *P < 0.05 vs. pGL3-
Control.
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niﬁcantly contribute to PAI-1 promoter activity. Deletion of a
sequence from 800 bp to 589 bp reduced promoter activity
by 55%, indicating the presence of transcription enhancer(s).
Enhancer activity was also noted in two other regions,
489 bp to 224 bp and 162 bp to 41 bp. A sequence
encompassing 589 bp to 489 bp confers a strong negative
regulatory activity. Deletion of this region increased PAI-1
promoter activity by 45%.
3.2. An E-box at 566 bp to 561 bp confers negative
regulatory activity of PAI-1 transcription in hMCs
To further characterize the cis-acting element(s) within
589 bp to 489 bp that mediates negative regulation of
PAI-1 transcription in hMCs, pGL3-Basic-552 and -524 were
constructed. Deletion of a sequence from 589 bp to
553 bp abolished the negative regulatory activity (Fig. 2A).
Further deletion of a region encompassing 552 bp to
490 bp, however, showed little eﬀect on PAI-1 promoter
activity, indicating that 589 bp to 553 bp is crucial for the
negative regulatory eﬀect of 589 bp to 489 bp. Bioinformat-
ics analysis showed that the PAI-1 promoter fragment 589 bp
to 489 bp contains the consensus E-box motif (5 0-CACGTG-
3 0) at 566 bp to 561 bp. Mutagenesis of this E-box by
substituting the central nucleotides (CACGTGﬁ CAATTG)
increased promoter activity of pGL3-Basic-800 by 39%
(P < 0.05) (Fig. 2B). This suggests that this E-box is a negative
regulatory element (NRE) of the PAI-1 gene in hMCs.
To determine whether or not the E-box is also a transcrip-
tional repressor of other genes, a sequence encompassing
589 bp to 553 bp of PAI-1 promoter containing WT or
mutated E-box was inserted into the 5 0-end of a heterogeneous
SV40 promoter of luciferase reporter vector pGL3-Control.
Luciferase activity of pGL3-Control containing WT E-box
(pGL3-Control PAI-1/553WT) was about 25% lower when
compared with pGL3-Control regardless of ionomycin stimu-
lation (P < 0.05) (Fig. 2C). Insertion of mutated E-box had no
signiﬁcant eﬀect on pGL3-Control luciferase activity. These
ﬁndings conﬁrm that this E-box is indeed the NRE.
3.3. Phosphorylation of USF-1 mediates the E-box-dependent
negative regulation of the PAI-1 gene expression
To identify nuclear factor(s) binding to the E-box, EMSA
was performed with a sequence encompassing 589 bp to
553 bp of native PAI-1 promoter containing the E-box motif.
The protein/DNA complexes were present with nuclear pro-
teins from both unstimulated and stimulated HMC-1 cells
(Fig. 3A). Speciﬁcity of this complex was conﬁrmed by adding
50· molar excess of unlabeled 37 bp PAI-1 promoter probe,
which eliminated the complex. Similar results were observed
with 50· molar excess of unlabeled E-box consensus sequence
ﬂanked by non-PAI-1 promoter sequences, whereas unlabeled
probes with mutated E-box did not eliminate the complex,
indicating that the E-box is essential in the formation of this
complex (Fig. 3B).
The E-box is the binding site of several basic helix–loop–
helix (bHLH) family transcription factors, including USF-1
and -2, Max, c-Myc, Mad, Mxi1, and TFE3 [18]. To identify
the transcription factor binding to the E-box at 566 bp to
561 bp of human PAI-1 promoter, supershift assay was
performed with antibodies against USF-1, USF-2 and TFE3.
Preincubation of anti-USF-1 antibody with nuclear proteinsresulted in complete supershift of the complex, but not with
anti-USF-2 antibody or anti-TFE3 antibody which are known
to bind to the E-box in other cell types (Fig. 3C). Pretreatment
of nuclear proteins with phosphatase eﬀectively inhibited the
formation of PAI-1 promoter-USF-1 complex (Fig. 3D). This
suggests that phosphorylation is required for USF-1 to bind to
the E-box of the PAI-1 promoter.
3.4. Overexpression of USF-1 aﬀects PAI-1 promoter activity
To further characterize the role of USF-1 and the E-box in
negative regulation of PAI-1 transcription, HMC-1 cells were
Fig. 3. Identiﬁcation of USF-1 as a transcription factor binding to the E-box at 566 bp to 561 bp of human PAI-1 promoter with EMSA. (A)
Nuclear proteins (NP) from resting cells (R) or ionomycin-treated HMC-1 cells (Io) were prepared. 32P-labeled 37 bp native PAI-1 fragment
(589 bp to 553 bp) was used as a probe. (B) As speciﬁc competitors, 50-fold excess of the unlabeled competitor containing consensus E-box
sequence (C), self-competitor (S), and competitor containing mutated E box sequence (M) were used. (C) Supershift analysis was performed with 2 lg
antibodies against USF-1, USF-2, or TFE-3 by preincubation with nuclear proteins before adding radiolabeled probes. (D) Nuclear proteins were
pretreated by 0.2 or 0.02 U of acid phosphatase for 25 min before adding radiolabeled probes. Free probes, protein/DNA complexes and supershifted
USF-1 are indicated by respective arrows. The results presented are representative of more than three independent experiments.
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pSG5-hUSF-1 or empty vector and pGL3-Basic-552, -589 with
WT E-box (589 WT), or 589 with mutated E-box (589 EMu)
(Fig. 4). Without overexpression of USF-1, promoter activity
of pGL3-Basic-589 WT was 26% lower than that of pGL3-
Basic-552 (Fig. 4, left panel). After USF-1 overexpression,
promoter activity of pGL3-Basic-589 WT was 40% lower than
that of pGL3-Basic-552 (Fig. 4, right panel). However, muta-
tion of the E-box abolished the negative regulatory activity of
pGL3-Basic-589 WT regardless of USF-1 overexpression.
These results suggest that the interaction between USF-1 and
the E-box at 566 bp to 561 bp mediates the negative regu-
lation of PAI-1 transcription in hMCs.4. Discussion
The cis-acting elements responsible for PAI-1 expression in
MCs are unknown, although a number of cis-acting elements
have been reported in the PAI-1 promoter in other cell types
[8–16]. In the present study, we showed, for the ﬁrst time, that
sequences encompassing 800 bp to 589 bp, 489 bp to
224 bp and 162 bp to 41 bp of the PAI-1 promoter are
responsible for positive regulation and a sequence encompass-
ing 589 bp to 489 bp is responsible for negative regulation
of PAI-1 transcription in hMCs. While further identiﬁcation of
the positive regulatory elements and their corresponding
transcription factors within three identiﬁed positive regulatory
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Fig. 4. Eﬀects of overexpression of USF-1 on promoter activity of
pGL3-Basic-552, -589 WT, and -589 EMu. HMC-1 cells were co-
transfected with human USF-1 overexpression vector pSG5-hUSF-1
or empty vector and PAI-1 promoter constructs pGL3-Basic-552,
-589WT, and -589EMu, and then stimulated with 2 lM ionomycin for
12 h. Luciferase activity was measured. The values are expressed by
means ± S.E. of ﬁve separate replicates.
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NRE within 589 bp to 489 bp of the PAI-1 gene in the cur-
rent study due to its novelty in hMCs. Several PAI-1 NREs
such as ethanol-associated element [14], Ets binding sites
[15], and E2F1 binding sites [16] have been reported in other
cell types. Here we present ﬁrst evidence that the sequence
589 bp to 489 bp suppresses PAI-1 transcription in hMCs.
Further deletion and site-directed mutagenesis indicated that
the E-box at 566 bp to 561 bp of the PAI-1 promoter is
the critical NRE motif responsible for negative regulation of
PAI-1 transcription in hMCs.
The E-box is a binding site of several basic helix–loop–helix
(bHLH) family transcription factors, including USF-1, USF-2,
and TFE3 in other cell types [18]. Our supershift assays found
that it is only USF-1 that binds to the E-box at 566 bp to
561 bp of the PAI-1 promoter in hMCs. The E-box core
motif CACGTG ﬂanked by non-PAI-1 sequences successfully
competed with native PAI-1 promoter fragment by abolishing
the formation of USF-1/PAI-1 promoter complex, whereas
mutated E-box did not. These results indicate that the intact
E-box motif is necessary and suﬃcient for USF-1 binding.
USFs were identiﬁed for their involvement in transcription
from the adenovirus major late promoter and puriﬁed as two
polypeptides of 43 and 44 kDa, termed USF-1 and USF-2,
respectively [19]. USFs bind to the E-box as homo-/hetero-di-
mers of USF-1 and USF-2. USF-1 has a potential to work as a
transcriptional activator or suppressor [18]. Here we demon-
strated that USF-1 homodimer binds to a functional E-box
at 566 bp to 561 bp of the PAI-1 promoter and suppresses
PAI-1 transcription in hMCs. Qi et al [20] reported that USF-1
binds to the E-box at 566 to 561 bp of the PAI-1 promoter
in quiescent human epidermal keratinocytes. After serum
stimulation, USF-1 binding is diminished and USF-2 binding
is increased. This resulted in increased PAI-1 transcription.
Together, USF-1 seems to participate in PAI-1 transcription
by inhibiting access of USF-2. In human hepatoma cells
(HepG2), this E-box is occupied by both USF-1 and USF-2,
although only USF-2 renders hypoxia-dependent PAI-1
expression [21]. We present ﬁrst evidence that, in hMCs,
USF-1 mediates negative regulatory activity of the PAI-1 gene
transcription through binding to the E-box at 566 bp to561 bp without interacting with other bHLH family tran-
scription factors.
We demonstrated that the intensity of the DNA–protein
complex between nuclear proteins from unstimulated and
stimulated HMC-1 cells was comparable, suggesting that in-
creased binding of USF-1 to the E-box is not required to medi-
ate the negative regulatory eﬀect. Our results are in agreement
with Allen et al’s [22] ﬁnding that TGF-b1 induces PAI-1 tran-
scription via binding of USF-1 to the E-box without aﬀecting
the binding of USF-1 to the E-box in human epidermal kerat-
inocytes. Interestingly, we also found that promoter activity of
pGL3-Basic-552, -589 WT, or -589 EMu was increased after
USF-1 overexpression (Fig. 4). This indicates the presence of
USF-1-dependent enhancer element(s) within 552 bp of the
PAI-1 promoter. Experiments to further characterize putative
USF-1-dependent enhancer(s) in the PAI-1 promoter are
underway in our laboratory.
In summary, we present ﬁrst evidence that PAI-1 is trans-
criptionally regulated via the positive regulatory elements
within 800 bp to 589 bp, 489 bp to 224 bp and
162 bp to 41 bp and the NRE within 589 bp to 489 bp
of the PAI-1 promoter in hMCs and that speciﬁc and constitu-
tive binding of the USF-1 homodimers to the E-box at
566 bp to 561 bp is the key mechanism of negative regula-
tion of PAI-1 expression in hMCs. Our ﬁndings suggest that an
interaction between USF-1 and the E-box at 566 bp to
561 bp may provide balancing eﬀects against increased
PAI-1 expression induced by a number of enhancers of the
PAI-1 promoter in patients with asthma.
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